TDDS Manufacturing: Solvent-Based Coating vs. Hot-Melt Adhesive — Which Route Fits Your Project?
Share
When a formulation team begins evaluating transdermal patch production equipment, one of the most persistent misconceptions they encounter is this: that "TDDS" (Transdermal Drug Delivery System) and "hot-melt adhesive" are synonymous — or that solvent-based coating is a niche, outdated alternative. Neither is accurate. Both routes produce legitimate TDDS patches, and the choice between them is a process-chemistry decision, not a regulatory classification one.
This article is for process engineers, formulation scientists, and procurement decision-makers comparing the two main manufacturing routes for matrix-type transdermal patches. Understanding the differences — and knowing which conditions favor each — is the foundational step before any equipment selection. The Huanghai MJ150 continuous wet-film coating platform represents one of these routes. This article explains why — and exactly when it is the right choice.
The Classification Error That Leads to Wrong Equipment Decisions
"TDDS" is a dosage form classification, not a manufacturing process descriptor. Published pharmaceutical literature — including peer-reviewed process reviews and regulatory guidance — explicitly identifies both solvent casting and hot-melt processes as the two primary manufacturing routes for passive matrix transdermal patches. Most modern commercial transdermal patches on market, regardless of which API they contain, are classified as TDDS. Many are produced via hot-melt. Many others are produced via solvent casting.
This distinction matters for procurement decisions because it prevents two common errors: - Error 1: Assuming that choosing a solvent-based platform means stepping outside the TDDS category. - Error 2: Assuming hot-melt is universally superior because it is more common at commercial scale.
The correct framing is: both routes converge on a TDDS end-point. The selection criterion is your API's physicochemical properties, your formulation development stage, and your manufacturing scale target.
Two Routes: A Technical Head-to-Head
The core process difference comes down to where heat is applied in the manufacturing sequence.
Hot-melt adhesive process: The pressure-sensitive adhesive (PSA) — typically a thermoplastic rubber or hot-melt acrylic — is mixed with the API at elevated temperature. The API must disperse into or dissolve within the molten adhesive matrix. The mixture is then cast onto the backing film and cooled to ambient temperature to solidify the matrix.
Solvent-based wet coating / solvent casting: The PSA — commonly a solvent-borne acrylate, silicone, or polyisobutylene (PIB) system — is dissolved in organic solvent. The API is added to this liquid adhesive solution at ambient or near-ambient temperature. The coating is then cast onto the backing film and passes through a heated drying tunnel to remove the solvent and form the dry adhesive matrix.
| Dimension | Hot-Melt Adhesive Process | Solvent-Based Wet Coating (Huanghai MJ150) |
|---|---|---|
| Processing temperature | Elevated — determined by the adhesive's melting point | Ambient mixing; heat applied only in the drying zone |
| API thermal requirement | Must be thermally stable throughout melt processing | Compatible with heat-sensitive APIs; drying temperature is independently controlled per zone |
| PSA chemistry | Thermoplastic rubber, hot-melt acrylic | Solvent-borne acrylate, silicone, PIB — full range of solvent-compatible PSA systems |
| Formulation state | Primarily solid dispersion in molten matrix | Solution or dispersion in liquid adhesive — higher molecular mobility during processing |
| Content uniformity | Strong in optimized, mature formulations | Inherently strong for complex dispersions; high adjustability at R&D and scale-up stages |
| Energy consumption | Lower — no continuous heated drying airflow required | Higher — continuous drying tunnel with temperature-profiled airflow |
| Throughput at scale | High for established, commodity-formula patches | Competitive; optimal for development-stage and mid-scale commercial |
| Equipment investment | Comparable | Comparable |
| Best for | Thermally stable APIs, mature formulations, high-volume output | Heat-sensitive APIs, solvent-based PSA systems, formulation-in-development, R&D flexibility |
Decision Framework: When Each Route Is the Right Choice
There is no universally superior route. The decision should be driven by the following clinical and process parameters:
Choose hot-melt when: - Your API has well-characterized thermal stability well above the adhesive's processing temperature - The formulation is mature, with a standardized PSA recipe that has been validated at scale - Commercial-scale throughput is the primary driver and energy efficiency per unit output is critical - The PSA system in your formulation is inherently thermoplastic
Choose solvent-based coating when one or more of the following apply: - The API or co-formulant exhibits sensitivity to elevated processing temperatures — estradiol, testosterone, nitroglycerin, scopolamine, nicotine, and lidocaine are documented examples in published literature where solvent-cast matrix patches are well-established - Your formulation requires a solvent-borne acrylate, silicone, or PIB PSA system — these are fundamentally incompatible with hot-melt processing - You are still in the formulation development phase and require adjustability in coating weight, drying temperature profile, or adhesive concentration that a hot-melt line cannot provide without dedicated re-tooling - You need independent zone-by-zone temperature control during drying — this is where Huanghai's patented hot-air gradient system (CN201668734U) provides specific technical value - The drug dispersion state in the adhesive matrix is complex — non-uniform dispersions, supersaturated systems, or multi-component adhesive blends where wet-phase mixing offers more control over final morphology - You are building a dual-use platform that needs to produce both ODF (oral dissolving film) and transdermal patches on the same equipment
The Huanghai MJ150 Platform: Where Solvent-Based Excels
The Huanghai MJ150 is a continuous wet-film coating machine designed for pharmaceutical-grade ODF and transdermal patch production. At 20,000 films/hour standard throughput (upgradeable), it operates on a solvent-based wet-coating process and incorporates two patented engineering features that are directly relevant to transdermal patch production:
Patent CN201668734U — Hot-Air Gradient Drying Tunnel: Unlike plate-based heating systems that apply heat stepwise and require manual zone adjustments, the MJ150's enclosed hot-air drying tunnel enables smooth progressive temperature profiling from the entry point (high drying rate) to exit (gentle, final moisture reduction). This eliminates the surface-hardening and solvent-trapping risks associated with abrupt temperature transitions — a known failure mode in solvent-based patch drying. Optional far-infrared enhancement can increase drying efficiency by 20–30% without extending tunnel length.
Patent CN117323228A — Multi-Formula Stripe Coating: For fixed-dose combination patches or research platforms requiring simultaneous multi-formula evaluation, this patented coating blade enables two formulations to be applied side-by-side in a single pass — eliminating the secondary drying cycle required in sequential multi-layer approaches.
For research and development teams not yet at commercial scale, the MJ150-Lab operates at 8,000–10,000 films/hour on the same process platform — allowing full process validation at pilot scale before transitioning to a commercial MJ150 line, with minimal parameter re-qualification.
Both platforms support full GMP compliance. Existing Huanghai transdermal patch production customers include Sinopharm and Shanghai Pharma Group, both of which operate Huanghai equipment for transdermal patch manufacturing.
For a full overview of the certifications and compliance standards our equipment meets, see our Certifications & Compliance page.
Frequently Asked Questions
Q: Does "TDDS" refer to a specific manufacturing process, or is it a product classification? A: TDDS is a regulatory and pharmacological product classification — it describes a drug delivery mechanism (transdermal systemic absorption) rather than how the patch is manufactured. Both solvent-based coating and hot-melt adhesive processing are established manufacturing routes for TDDS matrix patches. Published pharmaceutical manufacturing literature, including process review articles and patent precedents, explicitly lists both as the primary routes. Choosing a solvent-based coating platform does not place your product outside the TDDS category.
Q: For heat-sensitive APIs like estradiol or nitroglycerin, which manufacturing route is more appropriate? A: Solvent-based wet coating. Classic transdermal formulation patents for estradiol (e.g., matrix patches using organic-solvent PSA systems, cast onto backing film and oven-dried) and nitroglycerin (acrylate/vinyl acetate systems in solvent) follow the solvent-cast route. Hot-melt processing requires the API to maintain chemical integrity throughout melt dispersion, which introduces thermal stress that solvent-cast routes avoid entirely. If API thermal sensitivity is a known risk factor in your formulation, solvent-based is the technically conservative choice.
Q: Can the Huanghai MJ150 handle both ODF and transdermal patch production? A: Yes. The MJ150 platform supports both applications on shared core modules. Changeover between ODF and transdermal patch production requires preparation of two sets of specified component parts, with an estimated changeover time of approximately two man-days. This dual-platform capability is relevant for CDMOs and emerging pharmaceutical companies that want to serve both market segments without investing in two separate production lines. Contact us at https://drugmachines.com/pages/contact to discuss your specific configuration requirements.
Q: What is the practical difference between the MJ150 and MJ150-Lab for a formulation team starting transdermal development? A: The MJ150-Lab produces at 8,000–10,000 films/hour — appropriate for R&D batches and process validation work. It operates on the same wet-film coating principle and uses the same patented drying tunnel architecture as the MJ150 (20,000 films/hour), which means process parameters developed on the lab-scale unit translate directly to the commercial platform. For teams in early-phase transdermal development, the MJ150-Lab is the recommended entry point. See the full specifications at https://drugmachines.com/products/mj150-l-odf-film-coating-machine.
Q: Is hot-melt adhesive equipment a direct competitor to the MJ150 for all transdermal projects? A: Not for all projects. The two platforms serve overlapping but distinct formulation profiles. Hot-melt lines are a strong fit when the API is fully thermally stable, the PSA system is thermoplastic, and the project is targeting high-volume commodity production with a mature formula. Solvent-based coating is the stronger fit when API thermal sensitivity is a factor, the PSA system requires solvent-based chemistry, or the project is in active formulation development where process adjustability matters. A formulation team with the wrong equipment matched to their API chemistry will encounter problems that scale-up cannot easily resolve.
Conclusion
The solvent-based vs. hot-melt decision is not a choice between traditional and modern manufacturing — it is a technical matching problem between process chemistry and API/formulation requirements. Both routes produce compliant, commercially viable TDDS patches. Getting this match right at the development stage determines whether your manufacturing platform supports your product's pharmacokinetic targets or works against them.
For projects where thermal sensitivity, formulation complexity, or process flexibility is a factor, the Huanghai MJ150 platform offers a technically grounded solution — backed by two process patents and transdermal production references at major Chinese pharmaceutical groups.
Explore the MJ150 Transdermal Patch Coating Platform →
Or browse the full pharmaceutical film manufacturing solutions collection for the complete MJ Series lineup.
Interested in ODF or TDDS Film Coating Equipment?
The MJ150 supports both solvent-based ODF casting and transdermal patch film manufacturing in a single machine — scalable from pilot R&D to commercial production.